<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02050360</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC/12/26</org_study_id>
    <secondary_id>2013-000014-38</secondary_id>
    <secondary_id>12G01</secondary_id>
    <nct_id>NCT02050360</nct_id>
  </id_info>
  <brief_title>&quot;As Required&quot; Oral Sildenafil in Raynaud's Phenomenon</brief_title>
  <acronym>PROFIL</acronym>
  <official_title>Efficacy and Safety of &quot;as Required&quot; Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether &quot;on-demand&quot; sildenafil is effective in the
      treatment of Raynaud's phenomenon.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the Raynaud's Condition Score (RCS) during treatment, as compared to placebo.</measure>
    <time_frame>7 days</time_frame>
    <description>RCS is self-reported every day and averaged over 7-day periods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of RP: number of RP attacks during treatment, as compared to placebo.</measure>
    <time_frame>7 days</time_frame>
    <description>An attack is defined as an episode of pallor or cyanosis (with or without pain,tingling or numbness). The number of attacks is self-reported every day and averaged over 7-day periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' preference: comparison between the number of patients favoring a treatment to another.</measure>
    <time_frame>Every 3 weeks of treatment (week 3, 6 and 9)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain associated with RP: Mean change in the Raynaud's pain score during treatment, as compared to placebo.</measure>
    <time_frame>7 days</time_frame>
    <description>Pain associated with each attack is self-reported on a 10-point scale, and averaged over 7-day periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse drug events during treatment, as compared to placebo</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular reactivity: index of skin perfusion in response to local/regional cooling after a single dose of sildenafil, as compared to placebo (laboratory experiments)</measure>
    <time_frame>Week 1, 2 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Raynaud's Phenomenon</condition>
  <arm_group>
    <arm_group_label>Sildenafil 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil 40 mg</intervention_name>
    <arm_group_label>Sildenafil 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil 80 mg</intervention_name>
    <arm_group_label>Sildenafil 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active Raynaud's Phenomenon characterized by a clinical history of primary or
             secondary Raynaud's Phenomenon

          -  At least 7 RP attacks per week on 5 or more days per week (assessed over the 2 weeks
             preceding inclusion)

          -  Patients who have dated and signed the informed consent form

          -  Contraception for women

        Exclusion Criteria:

          -  Recently diagnosed RP (less than 2 months).

          -  Uncontrolled hypertension, diabetes mellitus, angina

          -  Haemodynamic instability

          -  Nonarteritic ischemic optic neuropathy

          -  Pulmonary hypertension

          -  Subjects currently taking sildenafil, tadalafil or vardenafil

          -  Subjects currently taking nitrates

          -  Subjects currently taking strong CYP3A inhibitors

          -  Pregnancy (or considering pregnancy in the next 4 months)

          -  Breast feeding

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc CRACOWSKI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM CIC03 - Unit√© de Pharmacologie Clinique</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigation Center - Pharmacology Unit - University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Raynaud's phenomenon</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Systemic Sclerosis</keyword>
  <keyword>Local cooling</keyword>
  <keyword>Microcirculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

